Literature DB >> 12112078

Combined effect of age and severity on the risk of dementia in Parkinson's disease.

Gilberto Levy1, Nicole Schupf, Ming-Xin Tang, Lucien J Cote, Elan D Louis, Helen Mejia, Yaakov Stern, Karen Marder.   

Abstract

Age and severity of extrapyramidal signs have been consistently associated with incident dementia in Parkinson's disease. We evaluated the separate and combined effects of age and severity of extrapyramidal signs on the risk of incident dementia in Parkinson's disease in the setting of a population-based prospective cohort study. Age and the total Unified Parkinson's Disease Rating Scale motor score at baseline evaluation were dichotomized at the median. Four groups of Parkinson's disease patients were defined: younger age/low severity (reference), younger age/high severity, older age/low severity, and older age/high severity. Risk ratios for incident dementia were calculated with Cox proportional hazards models controlling for gender, education, ethnicity, and duration of Parkinson's disease. Of 180 patients, 52 (28.9%) became demented during a mean follow-up period of 3.6 +/- 2.2 years. The median age at baseline of the Parkinson's disease patients was 71.8 years (range, 38.5-95.9 years), and the median total Unified Parkinson's Disease Rating Scale motor score was 24 (range, 2-65). The group with older age/high severity had a significantly increased risk of incident dementia (relative risk, 9.7; 95% confidence interval, 3.9-24.4) compared with the group with younger age/low severity (reference), whereas the groups with older age/low severity (relative risk, 1.6; 95% confidence interval, 0.5-4.8) and younger age/high severity (relative risk, 1.2; 95% confidence interval, 0.5-3.2) did not. These findings suggest that the increased risk of incident dementia in Parkinson's disease associated with age and severity of extrapyramidal signs is related primarily to their combined effect rather than separate effects.

Entities:  

Mesh:

Year:  2002        PMID: 12112078     DOI: 10.1002/ana.10219

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  48 in total

1.  Familial associations of Alzheimer disease and essential tremor with Parkinson disease.

Authors:  S Costello; Y Bordelon; J Bronstein; B Ritz
Journal:  Eur J Neurol       Date:  2010-03-17       Impact factor: 6.089

Review 2.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

3.  Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.

Authors:  Maurizio Zibetti; Aristide Merola; Valeria Ricchi; Alice Marchisio; Carlo Alberto Artusi; Laura Rizzi; Elisa Montanaro; Dario Reggio; Claudio De Angelis; Mario Rizzone; Leonardo Lopiano
Journal:  J Neurol       Date:  2012-07-08       Impact factor: 4.849

4.  Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia.

Authors:  Blanca Ramírez-Ruiz; María José Martí; Eduardo Tolosa; David Bartrés-Faz; Chistopher Summerfield; Pilar Salgado-Pineda; Beatriz Gómez-Ansón; Carme Junqué
Journal:  J Neurol       Date:  2005-07-05       Impact factor: 4.849

5.  Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.

Authors:  B Ravina; M Putt; A Siderowf; J T Farrar; M Gillespie; A Crawley; H H Fernandez; M M Trieschmann; S Reichwein; T Simuni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

Review 6.  Rivastigmine in Parkinson's disease dementia: profile report.

Authors:  M Asif A Siddiqui; Antona J Wagstaff
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 7.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

8.  Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease.

Authors:  K Hamada; M Hirayama; H Watanabe; R Kobayashi; H Ito; T Ieda; Y Koike; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

9.  Cognitive impairments in progression of Parkinson's disease.

Authors:  D A Stepkina; V V Zakharov; N N Yakhno
Journal:  Neurosci Behav Physiol       Date:  2010-01

Review 10.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.